Current Report Filing (8-k)
September 16 2020 - 12:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 16, 2020
TIMBER PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-37411
|
|
59-3843182
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
50 Tice Blvd, Suite A26
Woodcliff Lake, NJ 07677
(Address of principal executive offices)
Registrant’s telephone number, including
area code: (973) 314-9570
BioPharmX Corporation
900 E. Hamilton Ave., Suite 100
Campbell, California 95008
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.001 Par Value
|
|
TMBR
|
|
The NYSE American, LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01 Regulation FD Disclosure.
Timber Pharmaceuticals, Inc. has prepared
presentation materials (the “Investor Presentation”) that management intends to use with its presentation at the H.C.
Wainwright 22nd Annual Global Investment Conference to be held at 12:30 P.M. (EDT) on September 16, 2020. A copy of the Investor
Presentation is attached as Exhibit 99.1 hereto.
The information in this Current Report
on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange
Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of
1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any
filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as shall be expressly set forth
by a specific reference in such filing.
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Timber Pharmaceuticals, Inc. (formally known as BioPharmX Corporation)
|
|
a Delaware corporation
|
|
(Registrant)
|
|
|
Date: September 16, 2020
|
By:
|
/s/ John Koconis
|
|
Name:
|
John Koconis
|
|
Title:
|
Chief Executive Officer
|
|
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Apr 2023 to Apr 2024